ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has scheduled an FDA Allergenic Products Advisory Committee meeting to be held on 28 January 2014 to discuss the Biologic License Application (BLA) for the investigational ragweed sublingual allergy immunotherapy (AIT) tablet.
Help employers find you! Check out all the jobs and post your resume.
